16 results
8-K
EX-99.1
LYEL
Lyell Immunopharma, Inc.
7 Aug 24
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2024
4:06pm
, including ROR1+ relapsed/refractory platinum‑resistant ovarian cancer, endometrial cancer, multiple myeloma and chronic lymphocytic leukemia … myeloma and chronic lymphocytic leukemia,” said Lynn Seely, M.D., Lyell’s President and CEO. “In addition, our IND for LYL119, a next generation ROR1
8-K
EX-99.2
LYEL
Lyell Immunopharma, Inc.
26 Jun 24
Regulation FD Disclosure
8:32am
clinical trial of LYL797 in multiple myeloma and chronic lymphocytic leukemia IND submitted for LYL119, a next-generation ROR1-targeted product … of Exhaustion in Patients with Solid Tumors Compared to Those with Chronic Lymphocytic Leukemia (CLL) Solid Tumors: Cells Exhaust CLL: Cells Did Not Exhaust CD4
8-K
EX-99.1
LYEL
Lyell Immunopharma, Inc.
26 Jun 24
Regulation FD Disclosure
8:32am
cancer, multiple myeloma and chronic lymphocytic leukemia
IND submission completed for LYL119, Lyell’s next generation ROR1-targeted CAR T cell product … myeloma and chronic lymphocytic leukemia. This compelling early clinical data from LYL797 gives us a high degree of confidence to advance LYL119, our
8-K
EX-99.1
n0q5shhhfr8q q2b0
11 Sep 23
Regulation FD Disclosure
9:16am
10-K
fudy90ghdx
29 Mar 22
Annual report
4:20pm
424B4
aszr nzja2dvg
18 Jun 21
Prospectus supplement with pricing info
12:00am
S-1/A
2knricaxajh91487ri
9 Jun 21
IPO registration (amended)
7:12am
S-1
xl98b9njs2jhm6x
25 May 21
IPO registration
5:28pm
DRS/A
tvtjs8eq
12 May 21
Draft registration statement (amended)
12:00am
DRS
s90ejr229q8 zesv6eg
12 Apr 21
Draft registration statement
12:00am
- Prev
- 1
- Next